Introduction {#s1}
============

Individuals with substance use disorders exhibit emotional problems, including impaired emotional awareness ([@CIT0020]; [@CIT0016]) and alexithymia, which is considered to be a set of trait-like deficits in emotion processing ([@CIT0057]; G. J. [@CIT0062]; [@CIT0053]; [@CIT0012]). Features of alexithymia are thought to influence the emotional disposition to substance use ([@CIT0003]), possibly with substance abuse serving as a self-medication for alexithymia (G. J. [@CIT0063]). Helping to clarify the neurobiological basis of abnormalities in emotion processing associated with substance use disorders, therefore, ultimately may contribute to improved treatment strategies for individuals with these individuals.

Neuroimaging findings provide evidence that the combined action of the anterior cingulate cortex (ACC) and the anterior insular cortex (AIC) contributes to a facet of emotion processing associated with alexithymia. Those regions are conjointly activated in paradigms involving emotion processing ([@CIT0045]). Change in cerebral blood flow induced in ACC by presentation of exteroceptively and interoceptively emotional cues, and assessed using positron emission tomography (PET), is positively correlated with scores on the Levels of Emotional Awareness Scale ([@CIT0038]; [@CIT0044]), and the capacity for emotional experience ([@CIT0059]) is blunted in patients with traumatic injury or cerebrovascular insults in the frontal cortex, including ACC. Functional magnetic resonance imaging (fMRI) has been used to show AIC activation when subjects reexperience emotions by recalling personal emotional experiences ([@CIT0011]) and that self-reports of alexithymia and empathy are associated with activation in the AIC induced by viewing pleasant and unpleasant pictures ([@CIT0061]). Studies of brain structure have shown an association of alexithymia with smaller gray-matter volume in the ACC and AIC ([@CIT0004]; [@CIT0022]) and associations of cingulate-cortex and posterior-insula volumes with cognitive and affective dimensions of alexithymia ([@CIT0019]).

Individuals who have low emotional clarity, a latent construct of alexithymia, perform worse in tests of several executive domains, including self-monitoring and error recognition, than subjects with greater emotional clarity ([@CIT0036]). Therefore, impaired emotional processing and error monitoring would be expected to have some commonality in neuroanatomical substrates. ACC and AIC are key regions contributing to emotional awareness as well as sensitivity to errors in research participants with addictions (for review, see [@CIT0020]; [@CIT0046]). In one fMRI study, blunted sensitivity to punishment in a go/no-go task was associated with less activation in ACC and right AIC of cocaine users than in healthy controls ([@CIT0025]). Cocaine users have less capacity for inhibitory control and reduced error awareness than healthy-control subjects, as well as less task-related fMRI activity elicited in these regions by a go/no-go task ([@CIT0034]; [@CIT0024]). Notably, however, reduction in task-related ACC activity during an inhibitory-control task was greater in cocaine users who had impaired insight than in those without the impairment ([@CIT0046]). Moreover, a recent fMRI study demonstrated that intramodule connectivity in the salience network, including ACC and AIC, is negatively related to the Difficulty Describing Feeling scale in TAS-20 in cocaine users ([@CIT0041]).

Methamphetamine (MA) use disorder (ie, amphetamine-type substance use disorder, DSM-5) represents a substantial worldwide public health problem ([@CIT0054]). Compared with healthy controls, MA-dependent subjects exhibit structural and functional abnormalities in the ACC and insula ([@CIT0042]; [@CIT0048]; [@CIT0021]) and evidence of deficits in central dopaminergic transmission ([@CIT0006]). As postmortem studies of the human brain have shown dopaminergic projections to the ACC and insula and D2-type receptors in ACC and insula ([@CIT0018]; [@CIT0023]), it is plausible that dopaminergic dysfunction linked to MA use is linked to emotional-processing deficits associated with alexithymia. This view is supported by a high incidence of alexithymia in patients with neurological diseases that feature dopaminergic dysfunction, such as Parkinson's disease ([@CIT0008]).

In prior studies comparing MA-dependent subjects and healthy-control subjects, the MA group exhibited higher scores on one TAS-20 subscale, which indexes difficulty in identifying feelings ([@CIT0052]). MA-dependent subjects also show lower striatal dopamine D2-type receptor availability ([@CIT0066]; B. [@CIT0039]), raising the possibility that the two phenomena are related. Nonetheless, the role of dopaminergic signaling in emotion identification or processing had not been definitively tested in healthy control subjects or in those with addictions. We therefore tested the relationship between emotion processing, as measured by self-report on the TAS-20, and dopamine D2-type receptor availability in the ACC and AIC, comparing healthy control with MA-dependent participants using PET with \[^18^F\]fallypride, a radiotracer with sufficient affinity for D2-type receptors to allow measurement in extrastriatal regions ([@CIT0049]; [@CIT0050]).

Methods {#s2}
=======

Participants {#s3}
------------

All procedures were approved by the University of California Los Angeles (UCLA) Office for the Protection of Research Subjects. Participants, 18 to 55 years of age were healthy volunteers or individuals with MA dependence who were not seeking treatment. They were recruited using Internet and local newspaper advertisements, were assigned to 2 groups (control and MA), and received a detailed description of the study protocol. All participants provided written informed consent. The sample studied here overlaps with a previous study of dopamine D2-type receptors and impulsiveness (16 of 17 controls and 16 of 23 MA-group participants in this study) (B. [@CIT0039]) and another previous study of affect processing in MA-dependent individuals, in which the TAS-20 scale was administered (15 of 17 controls and 20 of 23 MA-group participants in this study) ([@CIT0052]).

Eligibility was determined using questionnaires, including the Structured Clinical Interview for DSM-IV Axis-I Disorders, to determine psychiatric diagnoses and a medical examination. Inclusion criteria for the MA group were current MA dependence, as indicated by DSM-IV criteria, and a positive urine test for MA at entry to the study. Exclusion criteria were any current Axis-I diagnosis (other than MA dependence or substance-induced mood or anxiety disorder in the MA group, or nicotine dependence in either group); use of psychotropic medications or illicit drugs other than MA or nicotine as indicated above, although light use of marijuana and alcohol was allowed (see below); central nervous system, cardiovascular, pulmonary, or systemic disease; human immunodeficiency virus seropositive status; severe hepatic impairment; chronic inflammation; pregnancy; and lack of English fluency. Use of marijuana or alcohol was allowed in both groups as long as it was below the threshold for a diagnosis of abuse or dependence as defined by DSM-IV.

All of the MA group participants were admitted to the UCLA General Clinical Research Center, where they maintained abstinence from MA and other drugs of abuse other than nicotine (in cigarettes) and caffeine (in beverages), as verified by urine screening. The control group participants were asked to visit the research sites on different days for psychological testing and imaging. On the days when brain-imaging or self-report data on the TAS-20 were collected, participants also provided urine samples negative for MA and other drugs. On completion of the study, participants were compensated with cash, gift certificates, and vouchers.

MRI and PET Imaging {#s4}
-------------------

Structural MRI scans were acquired on a 1.5-T Siemens Sonata tomograph for coregistration with PET images to define volumes of interest (VOI) (described below). A high-resolution sagittal T1-weighted 3D volumetric scan was acquired using a whole-brain magnetization-prepared rapid acquisition with gradient echo sequence (TR=1900ms, TE=4.38ms, flip angle=15, field of view=256×256×160, 160 slices, thickness=1mm).

PET scans were acquired using \[^18^F\]fallypride. The tomograph, a Siemens ECAT EXACT HR+ scanner, has an in-plane resolution full-width at half-maximum of 4.6mm, axial resolution full-width at half-maximum of 3.5mm, and axial field of view of 15.52cm in the 3-dimensional scanning mode. Participants were placed in the supine position, and their heads were immobilized using a thermoplastic mask that was marked for repositioning. A transmission scan for attenuation correction was conducted using a rotating ^68^Ga/^68^Ge rod source. Emission data were collected for 80 minutes after the radiotracer injection. Participants then were removed from the scanner for a 20-minute break, during which they were instructed to void their bladders to reduce radiation exposure. They returned to the scanner and were repositioned. After another transmission scan, additional emission data were collected for an 80-minute period to achieve the 180-minute scan duration required for an accurate measurement of binding potential using \[^18^F\]fallypride (details in PET data processing) ([@CIT0065]).

Self-Report Assessment {#s5}
----------------------

Capacity for emotional processing was assessed using the TAS-20 ([@CIT0001]), a widely used questionnaire that has been validated for testing of substance abusers ([@CIT0007]). The TAS-20 consists of 3 subscales that provide scores for corresponding factors: factor 1: difficulty identifying feelings; factor 2: difficulty describing feelings; and factor 3: externally oriented thinking. TAS-20 total score (the sum of the 3 subscale scores) is interpreted as follows: 0 to 51: no alexithymia; 52 to 60: possible alexithymia; 61 and higher: alexithymia (G. J. [@CIT0063]). The Beck Depression Inventory (BDI) ([@CIT0002]) was administered to verify depressive symptoms and potentially control for its confounding effects on TAS-20 scores because of indications that depression contributes to TAS-20 score ([@CIT0027]).

PET Data Processing {#s6}
-------------------

Reconstructed PET data were combined into 16 images, each reflecting data averaged over 10 minutes. FSL MCFLIRT (FMRIB Centre, Department of Clinical Neurology, University of Oxford, Oxford, UK) was used to correct for head motion. The PET images were coregistered to the structural MRI images using a 6-parameter, rigid-body spatial transformation (FSL FLIRT \[[@CIT0031]\]). A single VOI, defining ACC bilaterally in Montreal Neurological Institute (MNI) space, was based on the Harvard-Oxford Atlas. Separate VOIs for the anterior insulae were defined in MNI space using the definition specified by the functional connectivity analyses of [@CIT0013]. These VOIs were transformed to native space using FSL FNIRT. The primary regions investigated were the ACC and AIC because of their known roles in emotional self-awareness, but adhoc exploratory analysis was performed on the other regions, which have relatively high densities of dopamine D2-type receptors, including amygdala, hippocampus, globus pallidus, thalamus, and striatum. Bilateral VOIs for the exploratory regions were anatomically defined on each participant's MRI images using auto-segmentation procedures in FSL FIRST software ([@CIT0051]). Cerebellar VOIs were manually drawn on both hemispheres in MNI space, then transformed to native space. Striatum (caudate and putamen) and cerebellum VOIs were used in PET modeling (see below).

Time-activity data were extracted from motion-corrected, coregistered PET data and imported into PMOD Kinetic Modeling (PMOD Technologies Ltd., Zurich, Switzerland). Time-activity curves were first fit for the striatum, which has a high density of D2-type receptors. The simplified reference tissue model ([@CIT0037]) was used to provide an estimate of the rate constant k2′ for the transfer of the radiotracer from the reference-region tissue compartment to the plasma. The cerebellum was used as the reference region because of its low specific binding for \[^18^F\]fallypride ([@CIT0050]). The VOI time-activity curves were refit using the simplified reference tissue model 2 model ([@CIT0067]) using PMOD Kinetic Modeling, with the k2′value derived from the striatum applied to all VOIs. Binding potential (BP[nd]{.smallcaps}), an index of receptor availability, was then calculated as[R1\*]{.smallcaps}k2′/k2a --1, where R1=K1/K1′ is the ratio of tracer-delivery parameters from plasma to the target region and reference region, and k2a is the single-compartment rate constant for transfer from the target-region tissue compartment to plasma.

Statistical Analysis {#s7}
--------------------

Group differences in age, education, BDI, and TAS-20 scores were tested by unpaired Student's *t* tests, and group differences in sex and smoking status were evaluated by Fisher's exact test. Group differences in BP[nd]{.smallcaps} were tested by ANCOVA, controlling for age, sex, and smoking status, because of strong evidence for age-related decline of D2-type receptors in brain ([@CIT0056]; [@CIT0033]), for a sex difference in D2-type BP[nd]{.smallcaps} in cortical regions ([@CIT0032]) and for lower striatal D2-type BP[nd]{.smallcaps} among smokers than nonsmokers ([@CIT0015]; [@CIT0005]). The interaction between group and BP[nd]{.smallcaps} on emotional self-awareness was tested using ANCOVA, with TAS-20 total score as the dependent variable and age, sex, smoking status, the interval (in days) between the PET scan and TAS-20 assessment (which was not balanced between groups; see Results), subject group, BP[nd]{.smallcaps}, and the interaction of group and BP[nd]{.smallcaps} as the independent variables. Relationships between the TAS-20 scores and D2-type BP[nd]{.smallcaps} were tested using partial correlations controlling for age, sex, smoking status, and the interval between PET and TAS-20 assessment for the reasons given above. The criterion for statistical significance was *P*\<.05, 2-tailed. All statistical analyses were conducted using SPSS IBM 19 (IBM, Armonk, NY).

Results {#s8}
=======

Participants {#s9}
------------

Forty participants were recruited and assigned to a control group (n=17) and a MA group (n=23). The groups did not differ significantly in age or in sex distribution ([Table 1](#T1){ref-type="table"}). The control group included almost equal numbers of men and women, whereas there were twice as many men as women in the MA group. Cigarette smokers were more prevalent in the MA group. MA group participants reported using MA for 10.4 years (SD: 7.33; range: 2--24) and age of first MA use at 22.8 years (SD: 7.43; range: 13--38) and were abstinent from MA for 7.2 days (SD: 3.11; range: 4--15) before PET scanning and for 8.0 days (SD: 2.91; range: 4--17) before administration of the TAS-20. MA-group participants reported having used MA for 20.2 days (SD: 7.48; range: 5--30) in the month before entering the study, and the mean amount of MA use in the week before enrolling the study was 2.90g (SD: 3.36; range: 0--14.5). Fourteen MA group participants but none of the control subjects reported marijuana use within 1 month of entering the study, reporting use for 0.6 days (SD: 1.09; range: 0--4) in the last month. Due to scheduling needs of the participants and the imaging facility, the TAS-20 administrations and PET scans were conducted on different days. The interval between the PET scan and TAS-20 administration was 1.8 days on average for the MA group participants and significantly longer for the control group (32.5 days; unpaired Student's *t* tests *P*\<.001).

###### 

Demographic and Psychological Measures of Research Participants

                                               Control Group (n = 17)   MA group^*a*^ (n = 23)   Group difference: *P* value
  -------------------------------------------- ------------------------ ------------------------ -----------------------------
  Age (years)                                  32.1 (7.60)              35.6 (9.12)              0.21 ^*b*^
  Sex (male/female)                            9/8                      15/8                     0.52 ^*c*^
  Education (years)                            13.4 (1.75)              12.2 (3.42)              0.23 ^*b*^
  Cigarette smokers                            5                        20                       \< 0.001 ^*c*^
  TAS-20 total score                           32.41 (8.27)             39.79 (10.32)            0.02 ^*b*^
   Factor 1: Difficulty Identifying Feelings   7.94 (1.20)              11.30 (4.53)             0.01 ^*b*^
   Factor 2: Difficulty Describing Feelings    8.24 (3.78)              10.42 (5.45)             0.20 ^*b*^
   Factor 3: Externally Oriented Thinking      16.24 (5.08)             18.08 (5.20)             0.16 ^*b*^
  BDI                                          3.65 (3.90)              6.09 (5.62)              0.13 ^*b*^

Abbreviations: BDI, Beck Depression Inventory; TAS-20, 20-item Toronto Alexithymia Scale.

All data are shown as means (SD).

^*a*^MA use: age of first use was 22.8 (7.43); 20.2 (7.48) days of use in month before enrolling in study; 2.90 (3.36) g used in week before enrolling.

^*b*^Group difference evaluated by unpaired Student's *t* test.

^*c*^Group difference in distribution evaluated by Fisher's exact test.

Self-Report Assessments {#s10}
-----------------------

All control group participants and all but 5 of the MA group participants gave TAS-20 total scores consistent with no alexithymia (ie, ≤51); the remaining 5 MA group participants met the criteria for possible alexithymia. TAS-20 total scores were significantly lower for the control group than the MA group (t ~38~=-2.268, *P*=.03), with significantly lower scores for factor 1: difficulty identifying feelings (t ~35.884~=-3.255, *P*=.003: equal variances not assumed), but not for either of the other 2 factors (factor 2: t ~38~=-1.177, *P*=.25; factor 3: t ~38~=-1.109, *P*=.27) ([Table 1](#T1){ref-type="table"}), consistent with the findings obtained with the larger sample from which these participants were drawn ([@CIT0052]).

The TAS-20 total score was not significantly correlated with BDI score (r=-0.093, *P*=.57 by Pearson's correlation). The mean BDI scores, obtained close to the time of TAS-20 measurement, were 3.65 (SD: 3.90) and 6.09 (SD: 3.65) for the control and MA groups, respectively, and did not differ significantly between groups (t ~38~=-1.534, *P*=.133).

Dopamine D2-Type Receptor Availability and Association with TAS-20 Total Score {#s11}
------------------------------------------------------------------------------

In all analyses, left and right AIC VOI data were volume-weight averaged, because they were strongly correlated (r=0.884, *P* \< .001 by Pearson's correlation). There was no significant group difference in BP[nd]{.smallcaps} in the ACC (control: 0.53 \[SD: 0.13\]; MA: 0.51 \[SD: 0.13\]; F~1,\ 35~=0.136, *P*=.715), AIC (control: 0.75 \[SD: 0.15\]; MA: 0.69 \[SD: 0.19\]; F~1,\ 35~=1.616, *P*=.21), or other regions tested except for the striatum. In the striatum, the control group had a significantly higher BP[nd]{.smallcaps} than the MA group (control: 16.32 \[SD: 1.80\]; MA: 14.99 \[SD: 1.87\]; F~1,\ 35~=5.405, *P*=.03).

Taking TAS-20 total score as the dependent variable in the ANCOVA, there was a significant interaction between group (control vs MA) and BP[nd]{.smallcaps} in both the ACC (F~1,\ 31=~9.716, *P*=.004) and AIC (F~1,\ 31=~5.508, *P*=.03) ([Figure 1](#F1){ref-type="fig"}; [Table 2](#T2){ref-type="table"}). For the control group, significant positive partial correlations were found between TAS-20 total score and BP[nd]{.smallcaps} in both the ACC (r=0.626, *P*=.02) and AIC (r=0.619, *P*=.02), with these effects retaining significance after Bonferroni correction for multiple comparisons (ie, for the 2 VOIs). In the MA group, D2-type BP[nd]{.smallcaps} in the ACC (r=-0.302, *P*=.21) and AIC (r=-0.075, *P*=.76) showed nonsignificant negative partial correlations with the TAS-20 total score. Exploratory analyses of additional VOIs, with the TAS-20 total score as the dependent variable in ANOVA, indicated insignificant interactions between group and BP[nd]{.smallcaps} in the amygdala (F~1,\ 31=~2.950, *P*=.09), hippocampus (F~1,\ 31=~2.060, *P*=.16), globus pallidus (F~1,\ 31=~2.703, *P*=.11), thalamus (F~1,\ 31=~2.910, *P*=.10), and striatum (F~1,\ 31=~3.042, *P*=.09) ([Table 2](#T2){ref-type="table"}). Partial correlations between BP[nd]{.smallcaps} and the TAS-20 score were in the same directions as in primary regions: positive in the control group and negative in the MA group, although those correlations did not reach significance.

![D2-type receptor binding potential (BP[nd]{.smallcaps}) and association with Toronto Alexithymia Scale (TAS-20) total score. (*a*) Volumes of interest (VOIs) of the anterior cingulate cortex (ACC), anterior insular cortex (AIC), and striatum are shown on an averaged BP[nd]{.smallcaps} map of the control group (n=17). VOIs outlined in white. MNI coordinates: x=90, y=135, z=75 (mm). (*b*) Scatterplots showing individual data for the TAS-20 total score and BP[nd]{.smallcaps} in ACC and AIC. Blue circles represent data from individual participants in the control group, and red circles represent data from the MA group. BP[nd]{.smallcaps} was corrected for age, sex, smoking. Partial correlation analysis was used to determine r-values (\**P* \< .05, ^NS^ nonsignificant, with *P* values not corrected for multiple-region comparisons).](ijnppy_pyv129_f0001){#F1}

###### 

Association of Dopamine D2-type BP[nd]{.smallcaps} with the TAS-20 Total Score

                    Group-by-BP[nd]{.smallcaps} Interaction: *P* value   Correlation Coefficients   
  ----------------- ---------------------------------------------------- -------------------------- --------
  ACC               0.004 ^*a*^                                          0.626 ^*b*^                -0.302
  AIC               0.03 ^*a*^                                           0.619 ^*b*^                -0.075
  Amygdala          0.08                                                 0.191                      -0.335
  Hippocampus       0.11                                                 0.276                      -0.400
  Globus pallidus   0.07                                                 0.536                      -0.269
  Thalamus          0.09                                                 0.410                      -0.264
  Striatum          0.09                                                 0.307                      -0.191

Abbreviations: ACC, anterior cingulate cortex; AIC, anterior insular cortex; TAS-20, the 20-item of Toronto Alexithymia Scale.

The *P* values shown are not corrected for multiple comparisons (ie, tests in 2 regions: ACC and AIC).

^*a*^Significant interaction by ANCOVA controlling for age, sex, smoking status, and days of interval between PET and TAS-20.

^*b*^Significant correlation by partial correlation analysis, controlling for age, sex, smoking status, and days of interval between PET and TAS-20.

Discussion {#s12}
==========

The goal of this study was to determine whether dopamine D2-type receptors are involved in the processing of emotion and whether they may play a different role in MA-dependent individuals compared with healthy controls. The focus was on the ACC and AIC, which have been linked to emotion processing and awareness of internal states ([@CIT0009]; [@CIT0061]; [@CIT0045]) and which also show structural and functional deficits in individuals with MA use disorder ([@CIT0042]; [@CIT0048]; [@CIT0021]). A significant group difference in D2-type receptor availability, control group \> MA group, was found in striatum in agreement with previous studies ([@CIT0066]; B. [@CIT0039]) but not in any other regions tested, including ACC and AIC. While positive associations of D2-type receptor availability in ACC and AIC with the TAS-20 total score were observed for healthy control subjects, this relationship was not found among MA-dependent subjects, who exhibited higher TAS-20 total scores than control subjects. These findings suggest a difference in the contributions of dopaminergic transmission through D2-type receptors to the capacity of MA-dependent subjects in early abstinence to process feelings.

The positive relationship between D2-type BP[nd]{.smallcaps} and TAS-20 score in healthy subjects, implying that high receptor availability is associated with problems in emotion processing, is not immediately consistent with a report that L-dopa administration improves emotion perception in patients with Parkinson's disease ([@CIT0017]). This pharmacological finding suggests that in individuals with impaired dopaminergic neurotransmission, such as the MA-dependent subjects in our study, dopamine-enhancing interventions may help ameliorate deficits in emotion processing associated with identifying/describing feelings. On the other hand, if one considers D2-type BP[nd]{.smallcaps} as a neurochemical marker of potential for signaling through D2-type receptors, it would appear that high levels of D2-type BP[nd]{.smallcaps} contribute to alexithymia and less capacity for processing emotion. It is possible that optimal capacity for emotion processing is conferred by an optimal level of signaling through D2-type dopamine receptors in ACC and AIC, with exceedingly high levels linked to problems with emotion regulation. As none of the control participants met the criteria for alexithymia, however, the relationship may simply reflect a physiological correlation within the range of normality.

Given the lack of group differences in D2-type BP[nd]{.smallcaps} in the cortical regions assayed and the fact that the effects of MA use are not limited to the dopamine system, a disruption in the association of D2-type receptors with the TAS-20 score can reflect effects on other neurotransmitter systems, such as the GABAergic and glutamatergic systems, which interact with dopamine D2-type signaling ([@CIT0029], [@CIT0030]). As positive associations of both GABA and glutamate concentrations in both the ACC and left AIC with the TAS-20 score have been observed ([@CIT0014]), MA effects on these neurotransmitter systems may contribute to the observations made here.

The lack of association between D2-type BP[nd]{.smallcaps} and the TAS-20 score in MA-dependent subjects stands in contrast to observation of an inverse association between intramodule connectivity in the salience-network with the Difficulty Describing Feelings subscale score on the TAS-20 in cocaine-dependent individuals but not healthy controls ([@CIT0041]). Obvious differences between the studies are the type of stimulant and the fact that the primary self-report measure in the present study was the TAS-20 total score and not the Difficulty Describing Feeling subscale. In addition, the cocaine users were not required to maintain abstinence for several days prior to testing, and almost one-half of the cocaine group subjects had positive urine tests for cocaine on the testing day, whereas the MA-dependent subjects maintained supervised abstinence from all illicit drugs of abuse and alcohol for at least 4 days prior to testing. Aside from differences in potential effects of residual drug directly on behavior, there also might have been difference in the state of withdrawal in the two studies. Whether TAS-20 scores in this study were affected by acute withdrawal needs to be considered. Nevertheless, the TAS-20 score has been shown to be robust to substance withdrawal, especially for individuals without clinically significant alexithymia ([@CIT0012]). MA group participants actually were abstinent from MA for 8.0 days on average when the TAS-20 was administered; acute withdrawal symptoms from MA usually resolve within 1 week of initiating drug abstinence ([@CIT0068]). Nonetheless, future studies are warranted to determine how associations between D2-type receptor BP[nd]{.smallcaps} and measures of emotion processing vary with time of abstinence from MA.

There are limitations to this study, one of which is that TAS-20 scores were relatively low compared with those in previous studies ([@CIT0058]; [@CIT0014]), and most of the participants did not meet the criterion for clinical alexithymia. The range in TAS-20 scores, however, was similar to that in a previous study showing a correlation between a neurochemical marker and the TAS-20 total score ([@CIT0014]). In addition, for logistical reasons, there were some gaps in time between the self-report and PET measures, which ideally would have been collected on the same day. However, the time interval was controlled for statistically; and given the temporal stability of TAS-20 ([@CIT0064]), it is likely that this limitation is minimal. Another limitation is the small number of participants; necessitating the replication of our findings in a larger sample to demonstrate its reproducibility.

Finally, there are limitations associated with the use of \[^18^F\]fallypride and PET. Although \[^18^F\]fallypride has sufficient affinity for dopamine D2-type receptors to allow measurement in striatum and extrastriatal regions ([@CIT0050]), it does not distinguish between D2 and D3 receptor subtypes and does not resolve binding to receptors in different compartments, such as pre- vs postsynaptic receptors on different cellular elements in a region. Another factor to consider is that receptor availability, measured by BP[nd]{.smallcaps}, represents the receptor pool accessible to radiotracer, and as such it can be influenced by both receptor density and the concentration of intrasynaptic endogenous dopamine ([@CIT0028]). Indeed, \[^18^F\]fallypride binding in human cortex is responsive to change in intrasynaptic dopamine level induced by administration of amphetamine ([@CIT0055]; [@CIT0010]). However, on the basis of observations on the effect of dopamine depletion with α-methyltyrosine on the binding of \[^11^C\]raclopride, another D2-type receptor ligand ([@CIT0043]), the extent to which BP[nd]{.smallcaps} measured using this tracer would be affected by individual differences in intrasynaptic dopamine in the absence of a challenge would be expected to be small.

Despite these limitations, this study is the first to suggest a role of dopaminergic neurotransmission through D2-type receptors in capacity for identifying/describing feelings and to show that this relationship is disrupted in individuals with MA dependence. It has been hypothesized that substance-dependent individuals use drugs in an attempt to medicate themselves for unpleasant emotional states, which may be experienced as overwhelming due to impaired capacity to identify emotions ([@CIT0035]). To the extent that this assertion is correct, further studies are warranted to help clarify the neurobiological basis for the problems in emotional processing in individuals with MA-related and other substance use disorders.
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